Keerti V. Shah
National Institutes of Health
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Keerti V. Shah.
The Journal of Infectious Diseases | 1997
Xavier Castellsagué; Anthony M. Ghaffari; Richard W. Daniel; Franz X. Bosch; Nubia Muñoz; Keerti V. Shah
To investigate the role of men in cervical cancer, 816 husbands of women enrolled in four case-control studies of cervical neoplasia in populations at high (Colombia) and low (Spain) risk for cervical cancer were interviewed. Exfoliated cells from the penis were obtained and analyzed by polymerase chain reaction for the presence of human papillomavirus (HPV) DNA. Penile HPV DNA prevalences were higher in husbands of women with cervical neoplasia than in husbands of controls. Husbands of controls in Colombia had a 5-fold higher penile HPV DNA prevalence than the corresponding husbands in Spain. Strong dose-response relationships were found between penile HPV DNA prevalence and all sexual behavior-related variables in Spain but not in Colombia. Sexual promiscuity is the most important risk factor for penile HPV infections. Differences in HPV DNA prevalence in the male populations of Spain and Colombia are consistent with their 8-fold difference in cervical cancer incidences.
The Journal of Infectious Diseases | 1997
Keerti V. Shah; Richard W. Daniel; Howard D. Strickler; James J. Goedert
Recent reports of the detection of simian virus 40 (SV40) nucleotide sequences in ependymomas, choroid plexus tumors, osteosarcomas, and mesotheliomas have raised the possibility that SV40, which naturally infects Asian macaques, is circulating among humans. This possibility was examined by performing polymerase chain reaction assays on urine samples of 166 homosexual men, 88 of them human immunodeficiency virus (HIV)-seropositive, for genomic sequences of SV40 as well as of human polyomaviruses BK virus (BKV) and JC virus (JCV). Tests with masked urine specimens spiked with SV40-transformed cells were included to monitor the SV40 assay. SV40, BKV, and JCV sequences were identified, respectively, in 0, 14%, and 34% of the urine specimens. JCV viruria was far more common (37%) than BKV viruria (5%) in HIV-seronegative persons. HIV infection and more severe immunosuppression were associated with a higher frequency of BKV viruria. In summary, SV40 viruria was not detected among homosexual men who shed human polyomaviruses at a high frequency.
Journal of Clinical Oncology | 1997
Pau Viladiu; Franz X. Bosch; Xavier Castellsagué; Nubia Muñoz; J M Escribà; E Hamsíkova; V Hofmannova; Eloisa Guerrero; A Izquierdo; Carmen Navarro; P Moreo; Isabel Izarzugaza; Nieves Ascunce; Miguel Gili; M T Muñoz; Luis Alberto Tafur; Keerti V. Shah; V Vonka
PURPOSE To assess whether human papillomavirus (HPV) DNA detection in cervical cancer specimens, or antibodies to selected HPV 16 peptides are predictors of tumor recurrence and long-term survival in patients with squamous cell invasive cervical cancer. SUBJECTS AND METHODS Four hundred seventy-one cases included in two population-based case-control studies underwent follow-up evaluation. The survival and cause of death were ascertained for 410 cases (87%), with a median follow-up time of 4.6 years after diagnosis. HPV DNA was assessed using an L1 polymerase chain reaction (PCR)-based system and Southern hybridization (SH) on scraped cytologic specimens or biopsies. HPV 16 antibodies to E2, L2, and E7 peptides were detected with enzyme-linked immunosorbent assay (ELISA). RESULTS Clinical stage was the only independent prognostic factor for recurrence or survival. Although seropositivity to HPV 16 E7/3 peptide predicted a twofold excess risk of mortality (adjusted hazards ratio [HRa] = 2.0; 95% confidence interval [CI], 1.2 to 3.3), the association was restricted to stage I (HRa = 6.6; 95% CI, 1.2 to 37.6) and II (HRa = 5.9; 95% CI, 2.1 to 16.5) patients. The presence of HPV DNA (HRa = 0.9; 95% CI, 0.5 to 1.5), different estimates of the HPV viral load and the HPV type identified were not predictors of tumor recurrence or survival. CONCLUSION The presence of antibodies to HPV 16 E7 proteins is of prognostic value in early-stage cervical cancer. Our results provide strong evidence that detection and typing of HPV DNA in cervical cells or tissues is not a prognostic factor for recurrence or survival.
International Journal of Cancer | 2003
S de Sanjosé; Keerti V. Shah; E. Domingo-Domenech; Eric A. Engels; Af de Sevilla; Tomas Alvaro; Mercedes García-Villanueva; V. Romagosa; Eva González-Barca; Raphael P. Viscidi
The original article to which this Erratum refers was published in International Journal of Cancer (2002) 102(1) 29–33
Journal of Clinical Microbiology | 1995
Mark Schiffman; Nancy Kiviat; Robert D. Burk; Keerti V. Shah; Richard W. Daniel; Renee Lewis; Jane Kuypers; M. Michele Manos; David R. Scott; Mark E. Sherman; Robert J. Kurman; Mark H. Stoler; Andrew G. Glass; Brenda B. Rush; Iwona Mielzynska; Attila T. Lorincz
The Journal of Infectious Diseases | 1994
E. Hamšková; J. Novák; Vanda Hofmannová; Nubia Muñoz; F. X. Bosch; S. de Sanjosé; Keerti V. Shah; Z. Roth; V. Vonka
Archive | 2011
Karly S. Louie; Xavier Castellsagué; Silvia de Sanjosé; Rolando Herrero; Chris J. L. M. Meijer; Keerti V. Shah; Nubia Muñoz; F. Xavier Bosch
Archive | 2003
Dana E. Rollison; Kathy J. Helzlsouer; Anthony J. Alberg; Sandra C. Hoffman; Jean Hou; Richard W. Daniel; Keerti V. Shah; Eugene O. Major
Archive | 2001
Keerti V. Shah; Richard W. Daniel; Marie K Tennant; Nina Shah; Kelly T. McKee; Charlotte A. Gaydos; Joel C. Gaydos; Anne Rompalo
Archive | 1998
M.Michele Manos; Nubia Muñoz; Mark E. Sherman; A. E. Jansen; Julian Peto; Mark Schiffman; Victor Moreno; Robert J. Kurman; Keerti V. Shah